ArticleJournal of cancer research and clinical oncology2019

Clinical and biological characteristics of myeloma patients influence response to elotuzumab combination therapy.

Sophia Danhof et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.